GlassScriptPhysician profile
Michael J Raggio
NPI 1265493332
$11,382.59
in general payments reported to CMS, 2019-2025
39 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $420 · 2021: $752 · 2022: $1,157 · 2023: $1,400 · 2024: $4,994 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,570 · Education: $2,500 · Travel and Lodging: $783 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,570.08 |
| Education | $2,500.00 |
| Travel and Lodging | $782.64 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,418.70 | 2024 | |
| Glaxosmithkline, LLC. | $2,378.09 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $897.23 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Mylan Specialty L.P. | $852.58 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.37 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $424.58 | 2021-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $270.20 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $269.01 | 2019-2023 | Uptravi, Opsumit |
| Viatris Specialty LLC | $239.44 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Electromed, INC. | $197.93 | 2022-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $197.46 | 2021-2025 | Acthar |
| Genzyme Corporation | $196.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.38 | 2021-2025 | Dupixent |
| Amgen INC. | $129.67 | 2022-2025 | Tezspire |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $120.81 | 2020 | |
| Genentech USA, INC. | $112.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $87.27 | 2023-2024 | Zerbaxa, Recarbrio |
| Baxter Healthcare | $76.44 | 2023 | Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $73.71 | 2023-2025 | Wakix |
| Philips North America LLC | $59.15 | 2022-2023 | |
| United Therapeutics Corporation | $55.42 | 2020-2025 | Tyvaso, Tyvaso |
| Shionogi INC | $51.07 | 2023-2025 | Fetroja |
| Novartis Pharmaceuticals Corporation | $50.36 | 2019 | |
| Inspire Medical Systems, INC. | $44.23 | 2023-2025 | Inspire |
| Inari Medical, INC. | $41.48 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $37.25 | 2020-2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $35.75 | 2023-2024 | |
| Pfizer INC. | $30.33 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $28.28 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $26.79 | 2019 | |
| Axsome Therapeutics, INC. | $23.97 | 2023 | Sunosi |
| La Jolla Pharmaceutical Company | $20.17 | 2025 | Zevtera |
| Argenx US, INC. | $20.00 | 2024 | Vyvgart Hytrulo |
| Lilly USA, LLC | $19.37 | 2025 | Zepbound |
| Abbvie INC. | $18.45 | 2023 | |
| Insmed, INC. | $16.46 | 2023 | Arikayce |
| Verona Pharma, INC. | $15.64 | 2025 | Ohtuvayre |
| 3b Medical, INC. | $11.97 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.